Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 684

1.

New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.

Kopmar NE, Estey EH.

Clin Adv Hematol Oncol. 2019 Oct;17(10):569-575.

PMID:
31730583
2.

Need for routine examination of left ventricular ejection fraction in patients with AML.

Khan HM, Gardner KM, Shaw C, Halpern AB, Huebner EM, Percival MM, Mirahsani S, Sorror ML, Becker PS, Walter RB, Estey EH.

Leukemia. 2019 Nov 12. doi: 10.1038/s41375-019-0637-z. [Epub ahead of print] No abstract available.

PMID:
31719680
3.

Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

Bone Marrow Transplant. 2019 Nov 4. doi: 10.1038/s41409-019-0739-2. [Epub ahead of print] No abstract available.

PMID:
31685932
4.

Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia.

Bezerra ED, Othus M, Shawn C, Percival ME, Gardner K, Walter RB, Becker PS, Hendrie PC, Estey EH.

Clin Lymphoma Myeloma Leuk. 2019 Aug 1. pii: S2152-2650(19)30632-9. doi: 10.1016/j.clml.2019.06.014. [Epub ahead of print] No abstract available.

PMID:
31648955
5.

Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.

Krakow EF, Gyurkocza B, Storer BE, Chauncey TR, McCune JS, Radich JP, Bouvier ME, Estey EH, Storb R, Maloney DG, Sandmaier BM.

Am J Hematol. 2019 Oct 22. doi: 10.1002/ajh.25665. [Epub ahead of print]

PMID:
31637757
6.

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.

Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, Oehler VG, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, Hartley GA, Welch VL, Estey EH, Walter RB.

Leukemia. 2019 Oct 4. doi: 10.1038/s41375-019-0586-6. [Epub ahead of print] No abstract available.

PMID:
31586148
7.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C.

J Clin Oncol. 2019 Oct 10;37(29):2632-2642. doi: 10.1200/JCO.19.00416. Epub 2019 Aug 20.

PMID:
31430225
8.

Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.

Percival MM, Estey EH.

Cancer. 2019 Sep 15;125(18):3121-3130. doi: 10.1002/cncr.32354. Epub 2019 Jul 10. Review.

PMID:
31291012
9.

More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate.

Klepin HD, Estey E, Kadia T.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:421-432. doi: 10.1200/EDBK_239097. Epub 2019 May 17. Review.

PMID:
31099627
10.

Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification.

Sorror ML, Storer BE, Nyland J, Estey EH.

JAMA Oncol. 2019 Jul 1;5(7):1062-1064. doi: 10.1001/jamaoncol.2019.0902. No abstract available.

PMID:
31095246
11.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.208678. doi: 10.3324/haematol.2018.208678. [Epub ahead of print]

12.

Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.

Buckley SA, Mark NM, Othus M, Estey EH, Patel K, Walter RB.

Leuk Lymphoma. 2019 Sep;60(9):2304-2307. doi: 10.1080/10428194.2019.1581933. Epub 2019 Mar 11. No abstract available.

PMID:
30856024
13.

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F.

Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Review.

14.

New study-designs to address the clinical complexity of acute myeloid leukemia.

Estey E, Othus M, Gale RP.

Leukemia. 2019 Mar;33(3):567-569. doi: 10.1038/s41375-018-0363-y. Epub 2019 Jan 22. No abstract available.

PMID:
30670784
15.

'Looking beyond survival to define therapeutic value in acute myeloid leukemia'.

Estey E.

Leuk Lymphoma. 2019 May;60(5):1107-1109. doi: 10.1080/10428194.2018.1543886. Epub 2019 Jan 10. No abstract available.

PMID:
30628507
16.

Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come.

Hitzler J, Estey E.

Haematologica. 2019 Jan;104(1):7-9. doi: 10.3324/haematol.2018.205948. No abstract available.

17.

Outpatient induction and consolidation care strategies in acute myeloid leukemia.

Halpern AB, Walter RB, Estey EH.

Curr Opin Hematol. 2019 Mar;26(2):65-70. doi: 10.1097/MOH.0000000000000481.

PMID:
30585894
18.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. No abstract available.

19.

Acute myeloid leukemia: 2019 update on risk-stratification and management.

Estey EH.

Am J Hematol. 2018 Oct;93(10):1267-1291. doi: 10.1002/ajh.25214. Review.

20.

Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.

Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E.

Leukemia. 2019 Feb;33(2):371-378. doi: 10.1038/s41375-018-0275-x. Epub 2018 Oct 12.

21.

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.

Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2019 Feb;33(2):554-558. doi: 10.1038/s41375-018-0274-y. Epub 2018 Oct 12. No abstract available.

22.

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH.

Leuk Lymphoma. 2019 Apr;60(4):1023-1029. doi: 10.1080/10428194.2018.1516036. Epub 2018 Oct 2.

PMID:
30277112
23.

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML).

Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EH.

J Drug Assess. 2018 Jul 10;7(1):51-53. doi: 10.1080/21556660.2018.1492925. eCollection 2018.

24.

New drugs in AML: uses and abuses.

Estey EH, Gale RP, Sekeres MA.

Leukemia. 2018 Jul;32(7):1479-1481. doi: 10.1038/s41375-018-0168-z. Epub 2018 Jun 6. No abstract available.

PMID:
29875431
25.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.

PMID:
29859851
26.

Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia-Reply.

Sorror ML, Storer BE, Estey EH.

JAMA Oncol. 2018 Jul 1;4(7):1014-1015. doi: 10.1001/jamaoncol.2018.0677. No abstract available.

PMID:
29799988
27.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.

28.

Time to repeal and replace response criteria for acute myeloid leukemia?

Bloomfield CD, Estey E, Pleyer L, Schuh AC, Stein EM, Tallman MS, Wei A.

Blood Rev. 2018 Sep;32(5):416-425. doi: 10.1016/j.blre.2018.03.006. Epub 2018 Mar 27. Review.

29.

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1615-1620. doi: 10.1016/j.bbmt.2018.04.017. Epub 2018 Apr 21.

30.

Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.

Seo J, Smith BD, Estey E, Voyard E, O' Donoghue B, Bridges JFP.

Curr Med Res Opin. 2018 Dec;34(12):2031-2039. doi: 10.1080/03007995.2018.1456414. Epub 2018 Apr 27.

PMID:
29565196
31.

Widespread use of measurable residual disease in acute myeloid leukemia practice.

Epstein-Peterson ZD, Devlin SM, Stein EM, Estey E, Tallman MS.

Leuk Res. 2018 Apr;67:92-98. doi: 10.1016/j.leukres.2018.02.006. Epub 2018 Feb 13.

PMID:
29482173
32.

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.

Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, Becker PS.

Nat Commun. 2018 Jan 3;9(1):42. doi: 10.1038/s41467-017-02465-5.

33.

Allogeneic Transplantation for Acute Myelogenous Leukemia in CR1.

Estey E.

Biol Blood Marrow Transplant. 2018 Feb;24(2):205-206. doi: 10.1016/j.bbmt.2017.12.773. Epub 2017 Dec 14. No abstract available.

34.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

35.

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.

Percival ME, Estey E.

Clin Adv Hematol Oncol. 2017 Aug;15(8):632-642. Review.

PMID:
28949951
36.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

37.

Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Zhou Y, Wood BL, Walter RB, Becker PS, Percival ME, Bar M, Shaw C, Gardner K, Hendrie P, Abkowitz J, Appelbaum FR, Estey E.

Leukemia. 2017 Nov;31(11):2536-2537. doi: 10.1038/leu.2017.263. Epub 2017 Aug 18. No abstract available.

PMID:
28819284
38.

A case of indolent AML with five-year survival without treatment.

Bezerra ED, Smith H, Estey E.

Leuk Lymphoma. 2018 Feb;59(2):519. doi: 10.1080/10428194.2017.1330471. Epub 2017 Jun 22. No abstract available.

PMID:
28637370
39.

Day 14 bone marrow examination in the management of acute myeloid leukemia.

Terry CM, Shallis RM, Estey E, Lim SH.

Am J Hematol. 2017 Oct;92(10):1079-1084. doi: 10.1002/ajh.24818. Epub 2017 Jul 19. Review.

40.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

41.

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.

Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28. No abstract available.

PMID:
28351184
42.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G.

Leukemia. 2017 Jul;31(7):1659. doi: 10.1038/leu.2017.85. Epub 2017 Mar 24.

PMID:
28338082
43.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

44.

How good are we at predicting the fate of someone with acute myeloid leukaemia?

Estey E, Gale RP.

Leukemia. 2017 Jun;31(6):1255-1258. doi: 10.1038/leu.2017.56. Epub 2017 Mar 17. No abstract available.

PMID:
28303892
45.

Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.

Qu X, Othus M, Davison J, Wu Y, Yan L, Meshinchi S, Ostronoff F, Estey EH, Radich JP, Erba HP, Appelbaum FR, Fang M.

Cancer. 2017 Jul 1;123(13):2472-2481. doi: 10.1002/cncr.30626. Epub 2017 Feb 21.

46.

Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Percival ME, Lai C, Estey E, Hourigan CS.

Blood Rev. 2017 Jul;31(4):185-192. doi: 10.1016/j.blre.2017.01.003. Epub 2017 Feb 2. Review.

47.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F.

Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.

48.

Acute Myeloid Leukemia - Many Diseases, Many Treatments.

Estey E.

N Engl J Med. 2016 Nov 24;375(21):2094-2095. No abstract available.

PMID:
27959719
49.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

50.

Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?

Estey E.

Best Pract Res Clin Haematol. 2016 Dec;29(4):324-328. doi: 10.1016/j.beha.2016.10.003. Epub 2016 Oct 18. Review.

PMID:
27890254

Supplemental Content

Support Center